Please ensure Javascript is enabled for purposes of website accessibility

Regeneron and Sanofi Start Human Trials of Arthritis Drug as Possible COVID-19 Treatment

By Taylor Carmichael - Updated Mar 17, 2020 at 10:46AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Kevzara is being tested in a phase 2/3 trial to see if it's effective against the novel coronavirus.

Regeneron (REGN 0.60%) and Sanofi (SNY 1.55%) have started a clinical trial to see if Kevzara -- a drug that has been approved by the Food and Drug Administration as an arthritis treatment -- works on COVID-19. The companies hope that the monoclonal antibody will reduce fever and the need for supplemental oxygen in patients with severe cases of the illness. 

Because they are working with a drug that has already been approved, the companies can skip the phase 1 trial stage, in which a drug's safety profile is established. Kevzara already has a proven safety record in patients. The only question is whether it helps against COVID-19. 

Doctors in Hazmat suits treat sick patient

Image source: Getty Images

Right now, there are no approved drugs for COVID-19. In China, medical authorities have been trying drugs approved for other indications to treat patients with the disease. One is Actemra, an arthritis drug from Roche (RHHBY 3.26%). Actemra and Kevzara are highly similar pharmaceuticals -- interleukin 6 (IL-6) inhibitors approved as treatments for rheumatoid arthritis. 

The reason that researchers view IL-6 inhibitors as a promising avenue here is that the most severe cases of COVID-19 feature a dangerous and excessive immune reaction called a cytokine storm. Chinese health authorities have listed an elevated IL-6 condition as a sign of the disease getting worse. As inhibitors of IL-6, both Actemra and Kevzara might work to ease those patients' symptoms. 

In one small trial in China, medical authorities found that an IL-6 inhibitor rapidly reduced the fevers of COVID-19 patients. And 75% of patients had a reduced need for supplemental oxygen after taking the drug. 

Kevzara will be tested in approximately 400 patients at 16 sites around the country, starting in New York.   

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$56.29 (1.55%) $0.86
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
$686.02 (0.60%) $4.11
Roche Holding AG Stock Quote
Roche Holding AG
$43.23 (3.26%) $1.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.